FDA: Opdivo Approval Expanded to Include Lung Cancer

Share this content:
FDA: Opdivo Approval Expanded to Include Lung Cancer
FDA: Opdivo Approval Expanded to Include Lung Cancer

(HealthDay News) -- U.S. Food and Drug Administration approval of Opdivo (nivolumab) has been expanded to include advanced non-small-cell lung cancer (NSCLC), the agency said Wednesday in a news release. The drug was approved previously to treat advanced melanoma among people who don't respond to other medicines.

Opdivo inhibits the cellular pathway known as PD-1 protein on cells that prevents the immune system from attacking cancer cells, the agency said. The drug is sanctioned for people who have been treated with platinum-based chemotherapy.

Opdivo was clinically compared to another anti-cancer drug, docetaxel, in a study involving more than 270 people with NSCLC. People who received Opdivo lived an average of 3.2 months longer than people given docetaxel, the FDA said.

The most common side effects of Opdivo are fatigue, shortness of breath, musculoskeletal pain, loss of appetite, cough, nausea, and constipation. More severe adverse effects included immune reactions involving healthy organs, including the lungs, colon, liver, kidneys, and hormone-producing glands.

The drug is marketed by Bristol-Myers Squibb, based in Princeton, N.J.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ancient Gene Protects Elephants From Cancer

Ancient Gene Protects Elephants From Cancer

The LIF6 gene destroys cells with damaged DNA

Reasons for Undergoing Cosmetic Procedures Explored

Reasons for Undergoing Cosmetic Procedures Explored

Psychological and emotional motivations more likely in patients wanting acne scar tx, tattoo removal

DNR Orders Linked to Increased Mortality in Older Adults

DNR Orders Linked to Increased Mortality in Older ...

Early versus late DNR tied to shorter median length of stay in hospitalized adults aged 65 years and older

is free, fast, and customized just for you!




Already a member?

Sign In Now »